Close Menu

BMS

The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.

A plasma-based biomarker test for Alzheimer's could serve as a useful initial screen for the disease, as well as provide drugmakers with a way of selecting trial subjects that could be considerably less expensive than current methods like CSF analysis and PET scans.

The trial, called Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis to Define Unresponse Populations, or BATTER-UP, will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia.

Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."

Although some industry observers suggest that Boehringer Ingelheim's newly FDA-approved anticoagulant spells the end for PGx-guided warfarin dosing, some still see opportunities where warfarin administration, made more accurate with genetic testing, may be a better option for patients.

Kinaxo will apply its technologies to deconvolute molecular targets of compounds on which the drug company is currently performing drug discovery work.

Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.

Medco Research Institute announced this week that it is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor for the treatment of heartburn. The study will involve genetic testing to establish which patients can respond to Plavix.

Under the deal, Bristol-Myers Squibb will use siRNAs formulated with Tekmira's stable nucleic acid-lipid particle-based delivery technology to "validate the function of certain cellular targets."

Although Qiagen is prioritizing Rx/Dx partnerships with pharma, that doesn't mean it won't look into bringing tests to market with payors or on its own.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.